Elevated Pretherapy Serum IL17 in Primary Hepatocellular Carcinoma Patients Correlate to Increased Risk of Early Recurrence after Curative Hepatectomy
Figure 3
Proliferation of hepatocellular carcinoma cells in presence of activated IL17-producing T cells.
A: Diagram of the co-culture experiments. B, C: The proliferation of HCC cells, QGY-7703 or Hep3B cell lines, was determined using a CCK8 reagents after being co-cultured with IL17-producing T cells for 48 h. PBMCs were isolated from the HCC patients and cultured with recombinant human IL-23 in the presence of plate-bound anti-human CD3 and anti-human CD28 for 7–10 days. IL17 production was confirmed by intracellular staining (Figure S3). The proliferation of HCC cells (ctrl) containing anti-human CD3 and anti-CD28 antibodies in the medium but without adding cultured T cells in the upper chambers was used as control. All the antibodies used here were 5 µg/ml. Letter “c” represents isotype control. The upper chambers contained T cells were removed before CCK8 reagents were added. Triplicates were performed for each of the treatment. *: P<0.05. Data shown is representative one from 3 independent experiments.